Opportunity ID: 362195
This opportunity is no longer listed as open or forecasted.
General Information
| Funding Opportunity Number | HT942526ALSRPPCTA |
| Funding Opportunity Title | DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award |
| Agency | Jamie Shortall Grant Officer |
| Document Type | synopsis |
| Version | 2 |
| Opportunity Category | Discretionary |
| Opportunity Category Explanation | Not specified |
| Funding Instrument Type | Grant |
| Category of Funding Activity | Science and Technology and other Research and Development |
| Category Explanation | Not specified |
| Expected Number of Awards | 2 |
| Cost Sharing or Matching Requirement | No |
| Posted Date | May 04, 2026 12:00:00 AM EDT |
| Last Updated Date | Jun 17, 2026 02:47:07 PM EDT |
| Original Closing Date | Sep 30, 2026 12:00:00 AM EDT |
| Original Closing Date Notes | Not specified |
| Current Closing Date | Sep 30, 2026 12:00:00 AM EDT |
| Current Closing Date Notes | Not specified |
| Estimated Synopsis Date | Not specified |
| Estimated Application Due Date | Not specified |
| Estimated Award Date | Not specified |
| Estimated Project Start Date | Not specified |
| Archive Date | Oct 30, 2026 12:00:00 AM EDT |
| Estimated Total Program Funding | 5,600,000 |
| Award Ceiling | none |
| Award Floor | none |
Assistance Listings
- 12.420 — Military Medical Research and Development
Eligibility
| Eligible Applicants | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas:
· Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.
· Clinical Care: Improving aspects of clinical care and symptom management for ALS.
Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.
Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.
All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.
Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
Additional Information
| Contact | Jamie Shortall Grant Officer |
| Contact Information | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| help@eBRAP.org | |
| Email Description | eBRAP Help Desk |
| Phone | 301-619-2393 |
Additional information
Version History
Version history
| Opp hist id / Opportunity id | 362195 |
| Opp hist id / Revision | 0 |
| Opportunity id | 362195 |
| Revision | 0 |
| Opportunity number | HT942526ALSRPPCTA |
| Opportunity title | DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award |
| Owning agency code | DOD-AMRAA |
| Opportunity category / Category | D |
| Opportunity category / Description | Discretionary |
| Synopsis / Id / Opportunity id | 362195 |
| Synopsis / Id / Revision | 0 |
| Synopsis / Opportunity id | 362195 |
| Synopsis / Revision | 0 |
| Synopsis / Version | 1 |
| Synopsis / Agency code | DOD-AMRAA |
| Synopsis / Agency address desc | eBRAP Help Desk |
| Synopsis / Agency details / Code | AMRAA |
| Synopsis / Agency details / Seed | DOD-AMRAA |
| Synopsis / Agency details / Agency name | Defense Health Agency Contracting Activity – DHACA |
| Synopsis / Agency details / Agency code | DOD-AMRAA |
| Synopsis / Agency details / Top agency code | DOD |
| Synopsis / Agency contact phone | 301-619-2393 |
| Synopsis / Agency contact name | Jamie Shortall Grant Officer |
| Synopsis / Agency contact desc | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Synopsis / Agency contact email | help@eBRAP.org |
| Synopsis / Agency contact email desc | eBRAP Help Desk |
| Synopsis / Synopsis desc | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work. |
| Synopsis / Response date | Sep 30, 2026 12:00:00 AM EDT |
| Synopsis / Response date desc | Not specified |
| Synopsis / Posting date | May 04, 2026 12:00:00 AM EDT |
| Synopsis / Archive date | Oct 30, 2026 12:00:00 AM EDT |
| Synopsis / Cost sharing | No |
| Synopsis / Number of awards | 2 |
| Synopsis / Estimated funding | 5600000 |
| Synopsis / Estimated funding formatted | 5,600,000 |
| Synopsis / Award ceiling | none |
| Synopsis / Award floor | none |
| Synopsis / Applicant eligibility desc | Not specified |
| Synopsis / Create time stamp | May 06, 2026 08:12:48 AM EDT |
| Synopsis / Action type | U |
| Synopsis / Action date | Jun 17, 2026 02:47:07 PM EDT |
| Synopsis / Created date | May 04, 2026 09:42:10 AM EDT |
| Synopsis / Last updated date | May 04, 2026 09:42:10 AM EDT |
| Synopsis / Applicant types 1 / Id | 99 |
| Synopsis / Applicant types 1 / Description | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
| Synopsis / Funding instruments 1 / Id | G |
| Synopsis / Funding instruments 1 / Description | Grant |
| Synopsis / Funding activity categories 1 / Id | ST |
| Synopsis / Funding activity categories 1 / Description | Science and Technology and other Research and Development |
| Synopsis / Response date str | 2026-09-30-00-00-00 |
| Synopsis / Posting date str | 2026-05-04-00-00-00 |
| Synopsis / Archive date str | 2026-10-30-00-00-00 |
| Synopsis / Create time stamp str | 2026-05-06-08-12-48 |
| Cfdas 1 / Id | 433080 |
| Cfdas 1 / Opportunity id | 362195 |
| Cfdas 1 / Revision | 0 |
| Cfdas 1 / Cfda number | 12.420 |
| Cfdas 1 / Program title | Military Medical Research and Development |
| Synopsis modified fields | Not specified |
| Forecast modified fields | Not specified |
Attachment changes
| Id / Opportunity id | 362195 |
| Id / Att type | D |
| Id / Created date | Jun 17, 2026 02:50:06 PM EDT |
| Id / Att type desc | Related Documents |
| Id / Comments date | Jun 17, 2026 |
| Change comments | The regulatory application submission deadline was updated in Section 3.2.3 to clarify that IND, IDE, or equivalent applications, if required, must be submitted to the relevant regulatory agency by the Pilot Clinical Trial Award application submission deadline. |
Synopsis changes
revision
version
createTimeStamp
| Id | 362195 |
| Revision | 1 |
| Opportunity number | HT942526ALSRPPCTA |
| Opportunity title | DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award |
| Owning agency code | DOD-AMRAA |
| Opportunity category / Category | D |
| Opportunity category / Description | Discretionary |
| Synopsis / Opportunity id | 362195 |
| Synopsis / Version | 2 |
| Synopsis / Agency code | DOD-AMRAA |
| Synopsis / Agency name | Jamie Shortall Grant Officer |
| Synopsis / Agency phone | 301-619-2393 |
| Synopsis / Agency address desc | eBRAP Help Desk |
| Synopsis / Agency details / Code | AMRAA |
| Synopsis / Agency details / Seed | DOD-AMRAA |
| Synopsis / Agency details / Agency name | Defense Health Agency Contracting Activity – DHACA |
| Synopsis / Agency details / Agency code | DOD-AMRAA |
| Synopsis / Agency details / Top agency code | DOD |
| Synopsis / Top agency details / Code | DOD |
| Synopsis / Top agency details / Seed | DOD |
| Synopsis / Top agency details / Agency name | Department of Defense |
| Synopsis / Top agency details / Agency code | DOD |
| Synopsis / Top agency details / Top agency code | DOD |
| Synopsis / Agency contact phone | 301-619-2393 |
| Synopsis / Agency contact name | Jamie Shortall Grant Officer |
| Synopsis / Agency contact desc | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Synopsis / Agency contact email | help@eBRAP.org |
| Synopsis / Agency contact email desc | eBRAP Help Desk |
| Synopsis / Synopsis desc | Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work. |
| Synopsis / Response date | Sep 30, 2026 12:00:00 AM EDT |
| Synopsis / Response date desc | Not specified |
| Synopsis / Posting date | May 04, 2026 12:00:00 AM EDT |
| Synopsis / Archive date | Oct 30, 2026 12:00:00 AM EDT |
| Synopsis / Cost sharing | No |
| Synopsis / Number of awards | 2 |
| Synopsis / Estimated funding | 5600000 |
| Synopsis / Estimated funding formatted | 5,600,000 |
| Synopsis / Award ceiling | none |
| Synopsis / Award floor | none |
| Synopsis / Applicant eligibility desc | Not specified |
| Synopsis / Create time stamp | Jun 17, 2026 02:50:06 PM EDT |
| Synopsis / Mod comments | The regulatory application submission deadline was updated in Section 3.2.3 to clarify that IND, IDE, or equivalent applications, if required, must be submitted to the relevant regulatory agency by the Pilot Clinical Trial Award application submission deadline. |
| Synopsis / Created date | May 04, 2026 09:42:10 AM EDT |
| Synopsis / Last updated date | Jun 17, 2026 02:47:07 PM EDT |
| Synopsis / Applicant types 1 / Id | 99 |
| Synopsis / Applicant types 1 / Description | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" |
| Synopsis / Funding instruments 1 / Id | G |
| Synopsis / Funding instruments 1 / Description | Grant |
| Synopsis / Funding activity categories 1 / Id | ST |
| Synopsis / Funding activity categories 1 / Description | Science and Technology and other Research and Development |
| Synopsis / Response date str | 2026-09-30-00-00-00 |
| Synopsis / Posting date str | 2026-05-04-00-00-00 |
| Synopsis / Archive date str | 2026-10-30-00-00-00 |
| Synopsis / Create time stamp str | 2026-06-17-14-50-06 |
| Agency details / Code | AMRAA |
| Agency details / Seed | DOD-AMRAA |
| Agency details / Agency name | Defense Health Agency Contracting Activity – DHACA |
| Agency details / Agency code | DOD-AMRAA |
| Agency details / Top agency code | DOD |
| Top agency details / Code | DOD |
| Top agency details / Seed | DOD |
| Top agency details / Agency name | Department of Defense |
| Top agency details / Agency code | DOD |
| Top agency details / Top agency code | DOD |
| Synopsis attachment folders 1 / Id | 79532 |
| Synopsis attachment folders 1 / Opportunity id | 362195 |
| Synopsis attachment folders 1 / Folder type | Full Announcement |
| Synopsis attachment folders 1 / Folder name | FY26 ALSRP PCTA |
| Synopsis attachment folders 1 / Zip lob size | 629560 |
| Synopsis attachment folders 1 / Created date | May 04, 2026 09:42:27 AM EDT |
| Synopsis attachment folders 1 / Last updated date | Jun 17, 2026 02:49:39 PM EDT |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Id | 353129 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Opportunity id | 362195 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Mime type | application/pdf |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File name | HT942526ALSRPPCTA_GG2.pdf |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File description | FY26 ALSRP PCTA Program Announcement |
| Synopsis attachment folders 1 / Synopsis attachments 1 / File lob size | 797799 |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Created date | Jun 17, 2026 02:49:39 PM EDT |
| Synopsis attachment folders 1 / Synopsis attachments 1 / Synopsis att folder id | 79532 |
| Synopsis document urls | Not specified |
| Syn att change comments 1 / Id / Opportunity id | 362195 |
| Syn att change comments 1 / Id / Att type | D |
| Syn att change comments 1 / Id / Created date | Jun 17, 2026 02:50:06 PM EDT |
| Syn att change comments 1 / Id / Att type desc | Related Documents |
| Syn att change comments 1 / Id / Comments date | Jun 17, 2026 |
| Syn att change comments 1 / Change comments | The regulatory application submission deadline was updated in Section 3.2.3 to clarify that IND, IDE, or equivalent applications, if required, must be submitted to the relevant regulatory agency by the Pilot Clinical Trial Award application submission deadline. |
| Cfdas 1 / Id | 433080 |
| Cfdas 1 / Opportunity id | 362195 |
| Cfdas 1 / Cfda number | 12.420 |
| Cfdas 1 / Program title | Military Medical Research and Development |
| Opportunity pkgs | Not specified |
| Closed opportunity pkgs 1 / Id | 292624 |
| Closed opportunity pkgs 1 / Topportunity id | 362195 |
| Closed opportunity pkgs 1 / Family id | 14 |
| Closed opportunity pkgs 1 / Dialect | XFDL2.2 |
| Closed opportunity pkgs 1 / Opportunity number | HT942526ALSRPPCTA |
| Closed opportunity pkgs 1 / Opportunity title | DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award |
| Closed opportunity pkgs 1 / Cfda number | 12.420 |
| Closed opportunity pkgs 1 / Opening date | May 04, 2026 12:00:00 AM EDT |
| Closed opportunity pkgs 1 / Closing date | Sep 30, 2026 12:00:00 AM EDT |
| Closed opportunity pkgs 1 / Owning agency code | DOD-AMRAA |
| Closed opportunity pkgs 1 / Program title | Military Medical Research and Development |
| Closed opportunity pkgs 1 / Contact info | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Closed opportunity pkgs 1 / Grace period | 0 |
| Closed opportunity pkgs 1 / Electronic required | Y |
| Closed opportunity pkgs 1 / Expected application count | 12 |
| Closed opportunity pkgs 1 / Expected application size | 1000000 |
| Closed opportunity pkgs 1 / Open to applicant type | 1 |
| Closed opportunity pkgs 1 / Is multi project | N |
| Closed opportunity pkgs 1 / Extension | |
| Closed opportunity pkgs 1 / Mimetype | application/pdf |
| Closed opportunity pkgs 1 / Last update | May 04, 2026 09:43:37 AM EDT |
| Closed opportunity pkgs 1 / Workspace compatible flag | Y |
| Closed opportunity pkgs 1 / Package id | PKG00292624 |
| Closed opportunity pkgs 1 / Opening date str | 2026-05-04-00-00-00 |
| Closed opportunity pkgs 1 / Closing date str | 2026-09-30-00-00-00 |
| Original due date | Sep 30, 2026 12:00:00 AM EDT |
| Original due date desc | Not specified |
| Synopsis modified fields | revision; version; createTimeStamp |
| Forecast modified fields | Not specified |
| Error messages | Not specified |
| Syn post date in past | Yes |
| Doc type | synopsis |
| Forecast hist count | 0 |
| Synopsis hist count | 0 |
| Assist compatible | No |
| Assist url | Not specified |
| Related opps | Not specified |
| Ost | CLOSED |
Related Documents
Packages
| Agency Contact Information: | eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00292624 | May 04, 2026 12:00:00 AM EDT | Sep 30, 2026 12:00:00 AM EDT | View |
